Abstract The number of diagnosed inborn errors of metabolism (IEM) is growing constantly due to the improvement and widespread availability of analytical techniques. In 1982, a laboratory for the detection of IEM was set up in Porto Alegre, Brazil, and became a national reference centre for the diagnosis of these disorders. Ten thousand patients with signs and symptoms suggestive of IEM were investigated in our laboratory from 1982 to 1995 using speci®c protocols which included tests for the detection of glucosaminoglycans (GAGS), amino acids, sugars, oligosaccharides, sialyloligosaccharides, organic acids, as well as various metabolites. The biochemical investigation was completed in 9,901 patients and an IEM was detected in 647 cases (6.5%). Groups of IEM of higher incidence in our sample were lysosomal storage disorders (59.8%) and aminoacidopathies (21.2%). The disorders most frequently diagnosed were classical phenylketonuria, GM1 gangliosidosis, mucopolysaccharidosis type I, mucopolysaccharidosis type VI and metachromatic leukodystrophy. Conclusion This study shows that the establishment of reference centres for the investigation of rare genetic diseases is a suitable approach to the study of IEM in developing countries such as Brazil.
Introduction
Speci®c protocols for selective screening of inborn errors of metabolism (IEM) in high-risk patients have been introduced since 1950 in several countries. In the initial surveys, the techniques employed were simple and able to detect only a few diseases. A constant improvement of analytical equipment and techniques for assaying metabolites has allowed the diagnosis of an increasing number of disorders. A further improvement in the detection of these diseases has been achieved by the introduction of more elaborate procedures, such as tissue culture, speci®c enzyme assays and molecular analysis [6] .
The establishment of an accurate diagnosis is needed for the introduction of supportive and/or speci®c therapeutic measures. When a successful treatment is not available, genetic counselling and prenatal diagnosis can be oered for prevention of new cases in the index family. Therefore, selective screening for inherited metabolic diseases represents a major challenge to modern preventive medicine [6] . Reference centres for selective screening were set up in developed countries and, in most cases, became specialized in the detection of speci®c groups (such as aminoacidopathies, organic acidaemias, lysosomal storage disorders (LSD), peroxisomal disorders, etc.) or even for the diagnosis of a single disease.
Based on the experience of developed countries, a reference laboratory for the detection and diagnosis of IEM was set up in Porto Alegre, Southern Brazil. The laboratory is part of a University Hospital and has been receiving biological samples from patients at risk for IEM from all over Brazil since 1982.
We present here the reults obtained from analysis of samples from 10,000 high-risk patients referred to our centre from January 1982 to April 1995. In addition, we discuss the role of a reference laboratory for IEM in developing countries.
Material and methods
The patients studied were referred for investigation by several services from dierent regions of Brazil and from other countries in Latin America (Fig. 1) . Urine and plasma samples were obtained from 10,000 patients with signs and/or symptoms suggestive of a metabolic disorder and were at ®rst submitted to the``basic'' protocol. The tests included in this protocol (listed in Table 1 ) comprise qualitative screening tests of urine and amino acid paper chromatography of plasma and urine [7, 8] . Further investigations were carried out in the case of a positive or doubtful result in any of these tests, or when the speci®c metabolic disorder suspected was not investigated by tests included in this``basic'' protocol. In these cases, additional biological samples were requested, such as white blood cells (WBC), cerebrospinal¯uid (CSF) and/or skin biopsy, and analysed by selected speci®c assays of the``extended'' protocol ( Table 2 ). In addition, speci®c enzyme assays on leucocytes, erythrocytes, skin ®broblasts or liver biopsy were performed for con®rmation of a diagnosis (Table 3) . Occasionally, samples were sent to reference laboratories in other countries if complementary analyses become essential. Table 4 summarises the diagnoses performed in the current study. The results were obtained by the evaluation of 9,901 patients who completed the investigation.
Results
The study con®rmed the presence of 70 dierent metabolic disorders in 647 patients, corresponding to a frequency of 6.5%. These diagnoses were divided among the various groups of disorders, more than half of them being represented by the LSD group (59.8%). Other groups included aminoacidopathies (21.2%), organic acidaemias (5.7%) and disorders of carbohydrate metabolism (4.9%). Among the disorders most frequently diagnosed were classical phenylketonuria (PKU) (9.1%), GM1 gangliosidosis (9.1%), mucopolysaccharidosis type I (8.3%), mucopolysaccharidosis type VI (6.0%) and metachromatic leukodystrophy (4.9%).
Discussion
The estimated frequency of IEM in high-risk patients established in this study was 6.5%, a value similar to that reported by Wannmacher et al. [10] , who analysed a population from the same region of Brazil and estimated this frequency as being 5.9%. In addition, another study carried out by Chamoles et al. [2] in Argentina found a frequency of IEM of 6.25% among 14,928 high-risk patients carrying a metabolic abnormality, a ®gure also similar to our results. In a previous study by our group [5] , GM1 gangliosidosis was the disease with the highest incidence in our population. In the present investigation, PKU and Fig. 1 Location of the services which sent samples from the 10,000 high-risk patients referred for investigation of IEM GM1 gangliosidosis showed the same frequency in the study population, probably as the result of an increase in the proportion of newborns being submitted to neonatal screening for PKU in our country. This was also observed in other Latin American countries like Chile and Mexico [3, 4] . LSD were detected in 59.8% of our sample, representing the most frequent IEM group. Similar results have also been observed in Colombia, where this group of diseases, mainly represented by mucopolysaccharidoses, is more frequently reported [1] . On the other hand, in a dierent survey conducted by VelaÂ zquez et al. [9] using the questinaire of the Metabolic Information Network (MIN), LSD and amino acid disorders were found to be the most frequent disorders in Latin America. The questionaires used in this survey were completed by physicians from dierent Latin American countries (Argentina, Brazil, Chile, Colombia, Costa Rica, Cuba, Mexico and Venezuela).
We should emphasize that our laboratory was the ®rst to oer speci®c diagnosis of LSD in Brazil and soon became recognized as a specialized centre for these disorders. In addition, storage disorders are more``evident'' to the clinican since they usually causè`s yndromic'' (coarse) facies, hepato-and/or splenomegaly, macrocephaly or other signs which call the attention of clinicians.
It is possible that aminoacidopathies were also often diagnosed due to the simplicity and low-cost of the detection techniques required, such as chemical screening tests and amino acid chromatography.
Other statistics on the prevalence of IEM in European populations reveal that aminoacidopathies and organic acidaemias are the most frequent disorders among the IEM [6] . Since we have set up high-performance liquid chromatography and ion-exchange chromatography for amino acid quanti®cation and gas chromatography for organic acid detection, the number of aminoacidopathies and especially organic acid disorders identi®ed has grown steadily.
On the other hand, speci®cally regarding organic acidaemias, the rapid diagnosis of these clinically severe diseases in our laboratory has permitted prompt treatment in many cases and saved some lives. Before our facilities for organic acid detection were set up, suspected samples were sent abroad and not uncommonly many patients died before the diagnosis was made. This emphasizes the importance of setting up locally the techniques for the detection of severe and lethal disorders for which eective therapy is available.
The rarity, heterogenity and complexity of IEM are general problems to be addressed by services which work on the diagnosis of these diseases. The investigation of high-risk patients in specialized centres, allowing the combination of relatively low investment and high technical quality, seems to be an adequate alternative for Brazil, which is potentially applicable to other developing countries. 
